Inovio Pharmaceuticals CEO J Kim's 2018 pay falls 30% to $3.1M
Inovio Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: March 25, 2019
Inovio Pharmaceuticals reported fiscal year 2018 executive compensation information on March 25, 2019.
In 2018, four executives at Inovio Pharmaceuticals received on average a compensation package of $1.8M, a 19% decrease compared to previous year.
Average pay of disclosed executives at Inovio Pharmaceuticals
J. Joseph Kim, Chief Executive Officer, received $3.1M in total, which decreased by 30% compared to 2017. 50% of Kim's compensation, or $1.5M, was in stock awards. Kim also received $407K in non-equity incentive plan, $392K in option awards, $727K in salary, as well as $9.3K in other compensation.
For fiscal year 2018, the median employee pay was $118,696 at Inovio Pharmaceuticals. Therefore, the ratio of J. Joseph Kim's pay to the median employee pay was 26 to one.
Niranjan Y. Sardesai, Chief Operating Officer, received a compensation package of $1.3M, which decreased by 9% compared to previous year. 33% of the compensation package, or $448K, was in salary.
Mark L. Bagarazzi, Chief Medical Officer, earned $1.3M in 2018, a 7% decrease compared to previous year.
Peter D. Kies, Chief Financial Officer, received $1.3M in 2018, which decreases by 8% compared to 2017.
Related executives
You may also like
Source: SEC filing on March 25, 2019.